BridgeBio Pharma
BBIO
88 hedge funds and large institutions have $3.67B invested in BridgeBio Pharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 10 closing their positions.
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
65% more capital invested
Capital invested by funds: $2.22B → $3.67B (+$1.45B)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
17% more funds holding
Funds holding: 75 → 88 (+13)
1.71% less ownership
Funds ownership: 88.47% → 86.77% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$74.5M |
| 2 |
BlackRock
New York
|
+$32.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$19.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| 3 |
SM
SCGE Management
Menlo Park,
California
|
-$8.93M |
| 4 |
DM
Deerfield Management
New York
|
-$6.23M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.9M |
BBIO Hedge Fund Activity: Q4 2019 in Review
88 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2019, worth a combined $3.67B — up 65% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BBIO positions and 10 closed out — a net gain of 19 holders — while 31 added to existing stakes and 16 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $74.5M. The largest seller was Victory Capital Management, cutting an estimated $19.7M.
- 88 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2019, up from 75 in Q3 2019.
- Funds reported $3.67B of BridgeBio Pharma stock for Q4 2019, up 65% quarter-over-quarter.
- 29 funds opened new BridgeBio Pharma positions in Q4 2019 and 10 closed out, a net change of +19 holders.
- The largest BridgeBio Pharma buyer in Q4 2019 was Janus Henderson Group, an estimated $74.5M added.
- The largest BridgeBio Pharma seller in Q4 2019 was Victory Capital Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q4 2019.